CSL

#Alentis Therapeutics #Collaboration #CSL #Phase II trial

CSL and Alentis announce global partnership

CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases.  Under the terms of the agreement, Alentis will receive a… Read More

#Business & Investment #News #Trending News

Blood in a Petri dish
#Clinical trial #CSL #Haemophilia

Results confirm safety and durability of haemophilia drug 

Results from a Phase III trial have confirmed the durability and safety of a one-time infusion to treat adults living with moderate to severe haemophilia B.  Etranacogene dezaparvovec, developed by global biopharma company CSL, was studied in a Phase III open-label, single-dose, single-arm trial, with 54 male participants… Read More

#News

Monoclonal antibodies
#CSL #European Commission #Monoclonal antibodies #Rare disease

EC approves antibody to prevent hereditary angioedema attacks

The European Commission (EC) has approved Andembry (garadacimab), the only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.  Andembry inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema… Read More

#News #Regulatory

Gene therapy for haemophilia
#CSL #Gene therapy #Haemophilia #Scottish Medicines Consortium (SMC)

First gene therapy for haemophilia B accepted in Scotland

The Scottish Medicines Consortium (SMC) has accepted CSL Behring’s Hemgenix (etranacogene dezaparvovec) for use within NHS Scotland on an interim basis, until full marketing authorisation is granted. The single infusion gene therapy is recommended for adults with severe or moderately severe haemophilia B without a history… Read More

#News #Regulatory

Haemophilia
#CSL #Gene therapy #Haemophilia #National Institute for Health and Care Excellence (NICE)

UK health watchdog rejects gene therapy for haemophilia B

In a draft guidance consultation, the UK National Institute for Health and Care Excellence (NICE) has decided not to recommend the use of Hemgenix (etranacogene dezaparvovec) on the NHS for treating haemophilia B (congenital factor IX deficiency). Although the gene therapy was granted… Read More

#News #Regulatory #Trending News

Haematology
#Cell and gene therapy #CSL #Gene therapy #Haemophilia #MHRA #Phase III trial

First gene therapy for haemophilia B approved in Great Britain

CSL’s Hemgenix (etranacogene dezaparvovec) has been authorised as the first gene therapy for adults with severe and moderately severe haemophilia B (congenital Factor IX (FIX) deficiency) in Great Britain. It has been granted a marketing authorisation for patients without a history of FIX inhibitors by the… Read More

#News #Regulatory

Woman bleeding from the nose
#CHMP #CSL #Europe #European Commission #Haemophilia #Marketing approval authorisation

EU-approved gene therapy reduced haemophilia bleeds by 64%

The European Commission has granted conditional marketing authorisation for CSL’s Hemgenix (etranacogene dezaparvovec), the first one-time gene therapy for severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.   In an ongoing clinical trial, the drug reduced the… Read More

#Editor's Choice #News

Gene therapy for haemophilia
#Cell and gene therapy #CHMP #CSL #Europe #Gene therapy #Haemophilia

First gene therapy for haemophilia B gets go ahead in Europe

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The CHMP has recommended conditional marketing authorisation of CSL’s etranacogene dezaparvovec, a one-time gene therapy for the treatment… Read More

#News #Regulatory #Trending News